Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Debjit Chattopadhyay maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $55 to $51.
Guggenheim analyst Debjit Chattopadhyay maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $55 to $51.